Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.

MLA

Visvanathan, Kala, et al. “Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 4, Feb. 2023, pp. 784–90. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-2128.

APA

Visvanathan, K., Cope, L., Fackler, M. J., Considine, M., Sokoll, L., Carey, L. A., Forero-Torres, A., Ingle, J. N., Lin, N. U., Nanda, R., Storniolo, A. M., Tulac, S., Venkatesan, N., Wu, N. C., Marla, S., Campbell, S., Bates, M., Umbricht, C. B., Wolff, A. C., & Sukumar, S. (2023). Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 29(4), 784–790. https://doi.org/10.1158/1078-0432.CCR-22-2128

Chicago

Visvanathan, Kala, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A Carey, Andres Forero-Torres, et al. 2023. “Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29 (4): 784–90. doi:10.1158/1078-0432.CCR-22-2128.